Ocular implantation device

- Alimera Sciences, Inc.

An ocular implantation device comprises a housing having a longitudinal axis, a needle configured to receive an implant, and a plunger and a rod operatively coupled together. The plunger and the rod are disposed in the housing and are collectively, translationally moveable along the longitudinal axis of the housing. The rod is configured to be receivable within at least a portion of the needle to enable the rod to move the implant therethrough. An actuator is operatively engaged with the plunger such that movement of the actuator in a direction aligned with the longitudinal axis of the housing results in the translational movement of the plunger and the rod along the longitudinal axis of the housing in order to deliver the implant through the needle to a target site. An alternative embodiment of an ocular implantation device uses a retractable needle to deliver an implant.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
RELATED APPLICATIONS

The present patent document claims the benefit of the filing date under 35 U.S.C. §119(e) of Provisional U.S. patent application Ser. Nos. 60/986,464, filed Nov. 8, 2007, and 61/075,786, filed Jun. 26, 2008, which are hereby incorporated by reference in their entirety.

FIELD

The invention relates to a device for delivering ocular implants into the vitreous of the eye. Specifically, the invention relates to an ergonomically shaped injector containing a needle capable of puncturing the eye and delivering an implant into the vitreous of the eye.

BACKGROUND

A primary difficulty in treating diseases of the eye is the inability to introduce drugs or therapeutic agents into the eye and maintain these drugs or agents at a therapeutically effective concentration in the eye for the necessary duration. Systemic administration may not be an ideal solution because, often, unacceptably high levels of systemic dosing are needed to achieve effective intraocular concentrations thus increasing the incidence of unacceptable side effects of the drugs. Simple ocular instillation or application is not an acceptable alternative in many cases because the drug may be quickly washed out by tear-action or may otherwise be depleted from the eye into the general circulation. Suprachoroidal injections of drug solutions have been performed, but again the drug availability is short-lived. In summary, available methods make it difficult to maintain therapeutic levels of drug for adequate time periods.

Efforts to address this problem have lead to the development of drug delivery devices, or implants, which can be implanted into the eye such that a controlled amount of desired drug can be released constantly over a period of several days, weeks, or even months. Many such devices have been previously reported. See, for example, U.S. Pat. No. 4,853,224, which discloses biocompatible implants for introduction into an anterior segment or a posterior segment of an eye for the treatment of an ocular condition. In addition, U.S. Pat. No. 5,164,188 discloses a method of treating an ocular condition by introduction of a biodegradable implant comprising drugs of interest into the suprachoroidal space or pars plana of the eye. See also U.S. Pat. Nos. 5,824,072; 5,476,511; 4,997,652; 4,959,217; 4,668,506; and 4,144,317. Other methods include anchoring a plug or tack containing a drug into the sclera of the eye (see, e.g., U.S. Pat. No. 5,466,233).

Various sites exist in the eye for implantation of a drug delivery device or implant, such as the vitreous of the eye, anterior or posterior chambers of the eye, or other areas of the eye including intraretinal, subretinal, intrachoroidal, suprachoroidal, intrascleral, episcleral, subconjunctival, intracorneal or epicorneal spaces. Wherever the desired location of implantation, typical methods of implantation all require relatively invasive surgical procedures, pose a risk of excessive trauma to the eye, and require excessive handling of the implant. For example, in a typical method for placement in the vitreous, an incision is made through the sclera, and the implant is inserted into and deposited at the desired location in the vitreous, using forceps or other like manual grasping device. Once deposited, the forceps (or grasping device) is removed, and the incision is sutured closed. Alternatively, an incision can be made through the sclera, a trocar can be advanced through the incision and then the implant can be delivered through the trocar. Similar methods can be employed to deliver implants to other locations, e.g., implantation in the anterior chamber of the eye through an incision in the cornea.

There are numerous drawbacks of such techniques for implant delivery. Extensive handling of the implant is necessitated in these techniques, creating a risk that the implant will be damaged in the process. Many implants are polymer-based and are relatively fragile. If portions of the implants are damaged and broken-off, the effective therapeutic dose delivered by the implant once placed will be significantly altered. In addition, it becomes inherently difficult using these methods to achieve reproducible placement from patient to patient. Additionally, all of these techniques require an incision or puncture in the eye large enough to require suturing. Thus such techniques are typically performed in a surgical setting.

Many considerations affect the design and efficacy of an implant delivery device. First, it is important to ensure that the implant is consistently delivered to the subject with each application. Second, because implant therapy often requires numerous applications, the cost of providing the implant should also be considered.

Based on the foregoing, a need for a more facile, convenient, less invasive, and less traumatic means for delivering implants into the eye remains. In addition, a need for a more controlled means of delivering implants into the eye also remains.

BRIEF SUMMARY

The present invention is directed to a device and method for delivering ocular implants to desired locations in the eye. The device comprises a housing having an actuator that is communicatively linked to a plunger. A force applied to the actuator in a direction parallel to the longitudinal axis of the housing is used to deliver the implant to the desired location of the eye. Prior to delivery of the implant, the status of the implant is visually observable to a user.

In an aspect of the invention, an ocular implantation device comprises a housing having a longitudinal axis and a needle extending from the housing, wherein a lumen of the needle is configured to receive an implant. The device further comprises a plunger longitudinally disposed within the housing and a longitudinally extending rod operatively coupled thereto. The plunger and the rod are collectively, translationally moveable along the longitudinal axis of the housing. The rod is configured to be receivable within at least a portion of the lumen. The device also comprises an actuator configured for controlled, guided movement, such movement being controlled and guided by a user and by a portion of the housing. The actuator is operatively engaged with the plunger such that movement of the actuator in a direction aligned with the longitudinal axis of the housing results in translational movement of the plunger and the rod along the longitudinal axis of the housing. Further, the actuator is capable of movement in a direction normal to the longitudinal axis of the housing that does not result in movement of the plunger and the rod.

In another aspect of the invention, an ocular implantation device comprises a housing having a longitudinal axis and a needle extending longitudinally from the housing, with the needle having a lumen extending therethrough. The needle lumen is configured to receive an implant. The device further comprises a plunger longitudinally positioned within the housing and a rod extending therefrom. The plunger and the rod are translationally moveable along the longitudinal axis of the housing from an initial position, and the rod is receivable within at least a portion of the needle lumen. The device also comprises a guide shaft that is fixedly positioned within the housing in communication with the needle, with the guide shaft cooperatively receiving the plunger and the rod upon translational movement thereof and an actuator communicatively linked to the plunger. The actuator is longitudinally moveable from a first position relative to the housing upon application to the actuator of a force aligned with the longitudinal axis of the housing. Movement of the actuator corresponds with translational movement of the plunger from the initial position. The housing has a window disposed therein for visually determining the status of an implant disposed in the housing.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an exploded view of an ocular implantation device in accordance with an embodiment of the present invention.

FIG. 2 is a side elevational view of the ocular implantation device of FIG. 1 in an initial operational configuration with the left housing portion removed to better show internal components thereof.

FIG. 3 is a magnified partial view of FIG. 2 showing the implant in detail.

FIG. 4 is a side elevational view of the ocular implantation device of FIG. 1 in a subsequent operational configuration with the left housing portion removed to better show internal components thereof.

FIG. 5 is a magnified partial view of FIG. 4 showing the implant in detail.

FIG. 6 is a side elevational view of the ocular implantation device of FIG. 1 in another subsequent operational configuration with the left housing portion removed to better show internal components thereof.

FIG. 7 is a magnified partial view of FIG. 6 showing the implant in detail.

FIG. 8 is a side elevational view of the ocular implantation device of FIG. 1 in another subsequent operational configuration with the left housing portion removed to better show internal components thereof.

FIG. 9 is a magnified partial view of FIG. 8 showing the implant in detail.

FIG. 10 is a side elevational view of the ocular implantation device of FIG. 1 in another subsequent operational configuration with the left housing portion removed to better show internal components thereof.

FIG. 11 is a magnified partial view of FIG. 10 showing the implant in detail.

FIGS. 12-17 are perspective views of the ocular implantation device in accordance with alternative embodiments thereof.

FIG. 18 is an exploded view of an ocular implantation device in accordance with another embodiment of the present invention.

FIG. 19 is an exploded view of an ocular implantation device in accordance with another embodiment of the present invention, which embodiment is similar to the embodiment of FIG. 18.

FIGS. 20A-E are side elevational views of the ocular implantation device of FIG. 19 in various stages of operation, with the left housing portion removed to better show internal components thereof.

FIG. 21 is a magnified partial view of FIG. 20B showing the implant in detail.

FIG. 22 is a magnified partial view of FIG. 20C showing the implant in detail.

FIG. 23 is an exploded view of an ocular implantation device in accordance with another embodiment of the present invention.

FIGS. 24A-D are side elevational views of the ocular implantation device of FIG. 23 in various stages of operation, with the left housing portion removed to better show internal components thereof.

FIG. 25 is a magnified partial view of FIG. 24A showing the implant in detail.

FIGS. 26-27 are side elevational views of an ocular implantation device in accordance with another embodiment of the present invention in various stages of operation, with the right housing portion removed to better show internal components thereof.

FIG. 28 is a perspective view of an ocular implantation device in accordance with an alternative embodiment of the present invention, which embodiment is similar to the embodiment of FIG. 1.

FIG. 29 is a top plan view of the ocular implantation device of FIG. 28.

FIG. 30 is a side elevational view of the ocular implantation device of FIG. 28.

 DETAILED DESCRIPTION

An ocular implantation device is disclosed that provides a user a visual indication of the status of an implant to be delivered to a target tissue prior to delivery. The device further provides a tactile indication of the status of the implant to be delivered prior to delivery.

As used herein, the term “implants” refers to ocular implants or drug delivery devices that can be implanted into any number of locations in the eye and that may release a controlled amount of a bioactive agent or therapeutic immediately or over time. The term implants may include microimplants that have a sufficiently small cross-sectional area that they can be delivered by methods and/or using devices according to the invention that result in self-sealing of the eye at the puncture site associated with the delivery.

Although many implantable devices may be suitable for use with the ocular implantation device disclosed herein, devices having a tube shape, such as those described in U.S. Pat. No. 6,375,972, the subject matter of which is incorporated herein in its entirety, are preferred. An example of a tube shaped device includes a polyimide tube with a drug core contained therein. The drug core may be made by intermixing polyvinyl alcohol (PVA) with a drug substance such as fluocinolone acetonide. The core may be injected as a slurry into the tube and heated to crosslink the PVA. The tube may be cut to an appropriate length before or after insertion of the drug core. At each end of the tube, a drug permeable coating, for example, PVA may be applied. Alternatively, a permeable coating may be used at one end and an impermeable member may be placed at the other for a reduced rate of release.

As used herein, “self-sealing” methods of delivering implants into the eye refers to methods of introducing implants through a needle and into target tissue of a patient's eye without the need for a suture, or other similar closure means, at the needle puncture site. Such self-sealing methods do not require that the puncture site completely seal immediately upon withdrawal of the needle, but rather that any initial leakage is minimal and dissipates quickly such that a surgeon or another person equally skilled in the art would not be compelled to suture or otherwise provide other similar closure means to the puncture site. It is preferred that all embodiments of the device of the present invention provide self-sealing methods of delivering implants.

Referring now to the drawings, various illustrative embodiments will be described. In the figures herein, an implant is shown preloaded into the various device embodiments for descriptive and explanatory purposes. FIG. 1 depicts an embodiment of the ocular implantation device 10 comprising a housing 12, a plunger assembly 14, a guide shaft assembly 16, and an optional cap 18. The device 10 further comprises an actuator 20 disposed in an elongated housing opening 22 and a transparent window 24 for viewing an implant 26 (perhaps best shown in FIG. 3 or 5) within the housing 12. The housing 12 may comprise a right housing portion 28 and a left housing portion 30, which may be joined together to form the assembled housing 12. The plunger assembly 14 is disposed within the housing 12 at a proximal end 32 thereof when the device 10 is assembled. It comprises a plunger 34, an optional inserter plunger plug 36, and a spring 38. The plunger 34 and the optional inserter plunger plug 36 are configured to fit together. The plunger 34 is longitudinally disposed within the housing 12 and includes a plurality of radial projections 40, a closed end 42, and an open end 44 for receiving a longitudinally extending rod or wire 46. The rod 46 and the plunger 34 are operatively coupled such that movement of the plunger 34 results in movement of the rod 46 thereby resulting in the plunger 34 and the rod 46 being collectively, translationally moveable along the longitudinal axis 52 of the housing 12. An elongated opening or slot 48 is disposed near the closed end 42 of the plunger 34. The spring 38 has a flange portion 50 that may be inserted into the slot 48 of the plunger 34 to enable the spring 38 and the plunger 34 to be operatively connected to one another.

The plunger assembly 14 and the guide shaft assembly 16 are aligned with a longitudinal axis 52 of the housing 12. The guide shaft assembly 16 comprises the rod 46, a guide tube 54, a guide shaft 56, a needle stop 58, and a needle 60 and is disposed within the housing 12 when the housing 12 is assembled. When the device 10 is assembled, the plunger 34 and the rod 46 are translationally moveable along the longitudinal axis 52 of the housing 12 from an initial position, wherein the rod 46 is receivable within at least a portion of a lumen 70 of the needle 60. Additionally, the rod 46 is dimensioned to fit concentrically within the guide tube 54, and the guide tube 54 is dimensioned to fit concentrically within at least a portion of the guide shaft 56. The guide shaft 56 is fixedly positioned within and is supported by the housing 12, in particular by ribs 62 of the housing 12 and is in communication with the needle 60 when the device 10 is assembled. In addition, when the device 10 is assembled, the guide shaft 56 cooperatively receives the plunger 34 and the rod 46 upon translational movement thereof. The guide shaft 56 may include an upper guide shaft portion 64 and a lower guide shaft portion 66, with the lower guide shaft portion 66 optionally including a retention means for preventing the implant 26 from being unintentionally ejected from the device 10 or from being dislodged during shipping. In the exemplary embodiment, the retention means is a core dam 68 (perhaps best shown in FIG. 3 or 5). While the core dam 68 may prevent the implant from being unintentionally dislodged, it does not span the entire travel path of the implant 26. Thus during use of the device 10, the implant 26 may be moved beyond the core dam 68 for ejection from the device 10 by exertion of sufficient force upon the implant 26 by the rod 46.

The window 24 of the housing 12 enables a user to view the implant 26 in the housing 12 prior to its being moved into a lumen 70 (perhaps best shown in FIG. 3 or 5) of the needle 60, which is configured to receive the implant 26. Thus a user may view the implant 26 to ensure that it has not been damaged during shipping and handling or unintentionally ejected. The user may also use the window 24 to ensure that the implant 26 has been moved into the lumen 70 of the needle 60 and thus may be delivered to the target tissue, i.e., a user may look through the window 24 to make sure that the implant 26 is no longer visible and thus has been moved into the lumen 70 of the needle 60.

The guide shaft 56 is preferably open at both ends 72, 74. One end 72 of the guide shaft 56 slidably receives the guide tube 54, and the other end 74 is fitted with the needle stop 58. The needle stop 58 is axially aligned with the rod 46, the guide tube 54, and the guide shaft 56 and is disposed at a distal end 76 of the housing 12 when the device 10 is assembled. The needle stop 58 is configured to receive the needle 60 therethrough such that the needle 60 is positioned within the needle stop 58 and projects from the distal end 76 of the housing 12 when the device 10 is assembled. The needle stop 58 is configured to receive the rod 46 and an implant 26 during operation of the device 10 such that the implant 26 can be driven into the lumen 70 of the needle 60 by the rod 46 during operation. The implant 26 may contain a bioactive agent. The optional cap 18 is frictionally attached to the housing 12 thereby shielding the needle 60 when the device 10 is not being used.

The actuator 20 is preferably positioned partially within the housing 12 and is translationally moveable along the elongated opening 22 in the housing 12. The actuator 20 may be communicatively linked or operatively engaged with the plunger 34 such that movement of the actuator 20 in a direction aligned with the longitudinal axis 52 of the housing 12 results in translational movement of the plunger 34 and the rod 46 along the longitudinal axis 52 of the housing 12. The operative engagement may also enable the actuator 20 to be capable of movement in a direction normal to the longitudinal axis 52 of the housing 12 that does not result in movement of the plunger 34 and the rod 46. For example, the actuator 20 may be operatively engaged with the plunger 34 via one of the radial projections 40 of the plunger 34 and may be coupled to the flat spring 38 such that a force is applied to the actuator 20 by the spring 38.

When the device 10 is assembled, the actuator 20 may be longitudinally moveable from a first position 96 relative to the housing 12 upon application to the actuator 20 of a force aligned with the longitudinal axis 52 of the housing 12. The actuator 20 includes flanges 80 cooperatively engaging a portion of the housing 12 for controlling and guiding movement of the actuator 20. In the exemplary embodiment, the portion of the housing 12 is a track 82 disposed in the housing 12 for controlling and guiding movement of the actuator 20 during operation of the device 10. The track 82 is divided into continuous proximal and distal sections 84, 86 by a protrusion 88 disposed along the track 82. The protrusion 88 aids in preventing inadvertent delivery of the implant 26 by preventing the actuator 20 from accidentally moving along the track 82 from the proximal section 84 to the distal section 86 thereof. Finger gripping means 90 are optionally disposed on an exterior surface 92 of the housing 12 and an upper surface 94 of the actuator 20. The optional finger gripping means 90 aid in secure handling of the device 10 by a user.

The device 10 may further include a gauge or guide member 91 for assessing the location of the site of injection in relation to a landmark on the eye, preferably the limbus. FIGS. 28-30 show an embodiment of the ocular implantation device that is similar to the embodiment of FIG. 1 and that has a slightly different variation of the guide member than the guide member of FIG. 1. Preferably, an outer edge or a sight on the guide member 91 is aligned at or near the landmark, resulting in assessing a site for injection, which would be a predetermined distance from the landmark. Useful distances calibrated from a particular-sized guide member 91 are from about 10 mm to about 0.5 mm. Preferably from about 6 mm to about 2 mm. Most preferably about 4 mm. In the present embodiment, the guide member 91 includes a wing-shaped planar member disposed at the distal end 76 of the housing 12 in horizontal alignment with the longitudinal axis 52 of the housing 12. A user may use the guide member 91 to assist in determining the location of various parts of the eye in relation to one another, e.g., the cornea, the limbus, and the sclera, and in relation to the needle 60 of the device 10 to aid in precisely and accurately injecting the needle 60 into the eye for delivery of the implant 26.

FIGS. 2-11 show the device 10 in progressive stages of operation. In FIG. 2, the device 10 is in an initial configuration, with the actuator 20 positioned partially within the housing 12 at the proximal section 84 of the track 82. In FIG. 2, the actuator 20 is in the first position 96. In the first position 96, the flanges 80 of the actuator 20 are disposed within the housing 12 while much of the remainder of the actuator 20 is disposed exterior to the housing 12. In addition, the actuator flanges 80 are abutting the protrusion 88. Thus in order to move the actuator 20 toward the distal end 76 of the housing 12 thereby delivering the implant 26 to the target tissue, the flanges 80 should clear the protrusion 88. In the initial device configuration, the actuator 20 is acted upon by the flat spring 38 thereby maintaining the actuator 20 in the first position 96. A user may view the implant 26 in the housing 12 when the actuator 20 is in the first position 96, as shown in FIG. 3. Upon application of a downward force generally normal to the actuator 20, flanges 80 of the actuator 20 are vertically displaced below the protrusion 88, as shown in FIG. 4. In this configuration, more of the actuator 20 is disposed within the housing 12 than in the initial configuration shown in FIG. 2. Despite the fact that the actuator 20 moves downwardly relative to the longitudinal axis 52 of the housing 12, the plunger 34, which is operatively coupled to the actuator 20, does not move downwardly relative to the longitudinal axis 52 of the housing 12. In contrast, the plunger 34 remains vertically stationary with respect to the longitudinal axis 52 of the housing 12 throughout use and operation of the device 10. A user may use the window 24 to view the implant 26 in the housing 12 in this configuration, as shown in FIG. 5. As can be seen in FIGS. 3 and 5, the implant 26 is in the same location in the housing 12 when the housing 12 is in its initial configuration, shown in FIG. 2 and the instant configuration, shown in FIG. 4, i.e., movement of the actuator 20 downward relative to the longitudinal axis 52 of the housing 12 does not affect the location of the implant 26 during this stage of operation. As shown in FIG. 6, once the actuator flanges 80 are below the protrusion 88, a force applied to the actuator 20 in the direction of the distal end 76 of the housing 12 that is generally aligned with the longitudinal axis 52 of the housing 12 causes movement of the actuator 20, which causes translational movement of the plunger 34 and the rod 46 from the initial position in the proximal section 84 of the track 82 toward the distal end 76 of the housing 12. As described above, when the actuator 20 is in the first position 96, the track 82 guides movement of the actuator 20 in a direction normal to the longitudinal axis 52 of the housing 12 prior to movement of the actuator 20 in a direction aligned with the longitudinal axis 52 of the housing 12, which results in translational movement of the plunger 24 and the rod 46 along the longitudinal axis 52 of the housing 12.

During operation between the configurations of FIG. 4 and FIG. 6, the implant 26 is contacted by the rod 46, which moves the implant 26 into the lumen 70 of the needle 60 such that the implant 26 is primed for delivery to the target tissue, as can be seen in FIG. 7. The needle 60 may be modified, for example, with indent(s) (not shown) in the lumen 70 of the needle 60 to retain the implant 26 and prevent or eliminate accidental ejection or loss of the implant. After the actuator flanges 80 have cleared the protrusion 88, the spring 38 provides a tactile indication to the user that the implant 26 is primed for ejection as the actuator 20 is forced upwardly in a direction normal to the longitudinal axis 52 of the housing 12 to a second position 98 in the distal section 86 of the track 82 by the force of the spring 38, as shown in FIG. 8. Further, the relative movement, or lack thereof of the implant 26 is observable in the transparent window 24 of housing 12. More particularly, in FIGS. 2 to 5, the implant 26 is observable within the transparent window 24, and in FIGS. 6 to 9, the implant 26 has been driven into the lumen 70 of the needle 60 and is therefore not observable through the transparent window 24, thus indicating to a user that the implant 26 is primed to be delivered. In either event, the transparent window 24 aids in determining the location of the implant 26. The transparent window 24 may contain a magnifying lens. In FIGS. 6-9, the implant 26 is disposed in the lumen 70 of the needle 60 and is ready for ejection into a target site. Once the implant 26 is disposed thusly, a force applied to the actuator 20 that is generally aligned with the longitudinal axis 52 of the housing 12 and in the direction of the distal end 76 of the housing 12 further translates the plunger 34 and the rod 46 through the distal section 86 of the track 82, thereby driving the implant 26 through the lumen 70 of the needle 60 for ejection from the needle 60 and insertion into a target tissue. Thus, when the actuator 20 is in the second position 98, the track 82 guides movement of the actuator 20 in a direction aligned with the longitudinal axis 52 of the housing 12 for further translational movement of the plunger 34 and the rod 46 to deliver the implant 26.

To use the device 10, a user may insert the needle 60 of the device 10, when the device 10 is in the initial configuration shown in FIG. 2, into a subject's eye. In the initial configuration, the user may verify that the implant 26 is disposed in the housing 12 by using the window 24 of the device 10 to view the implant 26. In FIG. 2, the actuator 20 is in the first position 96. The user may apply a downward and a forward force to the actuator 20 to move the actuator 20 and hence the plunger 34 and rod 46 toward the distal end 76 of the housing 12. As described above, the plunger 34 is operatively connected to the rod 46, which drives the implant 26 through the lumen 70 of the needle 60 toward the target site as the actuator 20 is being moving toward the distal end 76 of the housing 12 by the user, ultimately resulting in the implant 26 being ejected from the device 10.

In the first position 96, the actuator 20 is disposed in the proximal section 84 of the track 82 in abutting relation with the protrusion 88. A user may press downwardly on the actuator 20 to move the flanges 80 below the protrusion 88. Once the flanges 80 clear the protrusion 88, a user may press the actuator 20 toward the distal end of the housing 12 thereby moving the actuator flanges 80 beyond the protrusion 88 (FIG. 6). The actuator's movement along the longitudinal axis 52 of the housing 12 causes or translates to similar movement of the plunger 34 and the rod 46 along the longitudinal axis 52 of the housing 12 resulting in the rod 46 pushing the implant 26 into the lumen 70 of the needle 60 thereby priming the implant 26 for ejection. The user may verify that the implant 26 is no longer in the housing 12 by looking through the window 24 of the housing 12. After the user has moved the actuator 20 beyond the protrusion 88, the spring 38 forces the actuator 20 into the second position 98, wherein the actuator 20 is disposed in the distal section 86 of the track 82 with the flanges 80 thereof disposed above the protrusion 88 (FIG. 8). The user may continue to press the actuator 20 toward the distal end 76 of the housing 12 thereby causing further translational movement of the plunger 34 and the rod 46 thus delivering the implant 26 to the target site, as shown in FIGS. 10 to 11. Preferably, the puncture site is self-sealing upon removal of the needle 60.

FIGS. 12-17 are perspective views of the ocular implantation device in accordance with alternative embodiments thereof. Similarly to the embodiment shown in FIG. 1, the ocular implantation devices of FIGS. 12-17 comprise a housing 102, an actuator 104 disposed in an elongated housing opening 128, a transparent window 106 for viewing the implant 26 within the housing 102, and an optional cap 112. Components that are substantially similar to those of the embodiments of FIGS. 18 and 19 are designated with the same reference numerals as used in FIGS. 18 and 19. The devices include various embodiments of finger gripping means optionally disposed on an exterior surface of the housing and an upper surface of the actuator to aid in secure handling of the device by a user.

FIGS. 18 and 19 are exploded perspective views of the ocular implantation device in accordance with alternative embodiments thereof. The devices 100 of FIGS. 18 and 19 are substantially similar; however, the optional finger gripping means 170, 172 present in the two embodiments are somewhat different. FIG. 18 substantially corresponds to the embodiment shown in FIG. 12 and FIG. 19 substantially corresponds to the embodiment shown in FIG. 13. Components that are the same as one another or substantially similar in the devices of FIGS. 18 and 19 share the same reference numeral.

Both embodiments comprise a housing 102, an actuator 104, a window 106, a plunger assembly 108, a guide shaft assembly 110, and an optional cap 112. The housing 102 may comprise a right housing portion 114 and a left housing portion 116, which may be joined together to form the assembled housing 102. The plunger assembly 108 is disposed within the housing 102 at a proximal end 118 thereof when the device 100 is assembled. It comprises a plunger 120 and a spring 122. The plunger 120 includes a plurality of radial projections 124, a closed end 126 having an elongated opening or slot 128 formed therein, and an open end 130 for receiving an extendedly projecting rod or wire 132 and a rod holder 134. In addition, the open end 130 of the plunger 120 is dimensioned to be slidably received by a guide shaft 136 of the guide shaft assembly 110. The spring 122 has a flange portion 138 that may be inserted into the slot 128 of the plunger 120 to enable the spring 122 and the plunger 120 to be operatively connected to one another.

The plunger assembly 108 and the guide shaft assembly 110 are aligned with a longitudinal axis 140 of the housing 102. The guide shaft assembly 110 comprises the rod 132, the rod holder 134, the guide shaft 136, a needle stop 142, and a needle 144 and is disposed within the housing 102 when the housing 102 is assembled. The rod 132 is dimensioned to fit concentrically within the guide shaft 136. The guide shaft 136 is fixedly positioned within and is supported by the housing 102, in particular by ribs 146 of the housing 102.

The guide shaft 136 is preferably open at both ends 148, 150. One end of the guide shaft 148 slidably receives the plunger 136, and the other end 150 is fitted with the needle stop 142 for accommodating the rod 132 and an implant 152 prior to the implant 152 being moved into a lumen 154 (perhaps best shown in FIG. 21) of the needle 144. The needle stop 142 is axially aligned with the rod 132, the rod holder 134, and the guide shaft 136. The needle 144 is positioned in the needle stop 142 and projects from a distal end 156 of housing 102. The needle stop 142 is configured to receive the rod 132 and the implant 152 during operation of the device 100 such that the implant 152 can be driven into the lumen 154 of the needle 144 by the rod 132 during operation. The implant 152 may contain a bioactive agent. The optional cap 112 is frictionally attached to the housing 102 thereby shielding the needle 144 when the device 100 is not being used.

The actuator 104 is preferably positioned partially within the housing 102 and is translationally moveable along an elongated opening 158 in the housing 102. The actuator 104 may be operatively coupled to the plunger 120 via one of the radial projections 124 and may be coupled to the flat spring 122 such that a force is applied to the actuator 104 by the spring 122. The actuator 104 includes flanges 160 cooperatively engaging a track 162 disposed in the housing 102. The track 162 aids in guiding the actuator 104 during operation of the device 100. In the instant embodiment, the track 162 is divided into continuous proximal and distal sections 164, 166 by a protrusion 168 disposed along the track 162. Finger gripping means 170, 172 are optionally disposed on an exterior surface 174 of the housing 102 and an upper surface 176 of the actuator 104. The optional finger gripping means 170, 172 aid in secure handling of the device 100 by a user. As indicated previously, the finger gripping means 170, 172 of the embodiments shown in FIGS. 18 and 19 differ and thus have different reference numerals.

FIGS. 20A-E, 21, and 22 show the device 100 in progressive stages of operation. In FIG. 20A, the device 100 is in an initial configuration, with the actuator 104 positioned partially within the housing 102 in the proximal section 164 of the track 162. In this initial configuration, the actuator 104 is acted upon by the flat spring 122 such that a force is applied to the actuator 104. Upon application of a force that is generally normal to the actuator 104, flanges 160 of the actuator 104 are vertically displaced below the protrusion 168. Upon application of a force that is generally aligned with the longitudinal axis 140 of the housing 102, the actuator 104 is moved from the proximal section 164 of the track 162 toward the distal end 156 of the housing 102 thereby clearing the protrusion 168, as shown in FIG. 20B. During this operation, the implant 152 is contacted by the rod 132, as shown in FIG. 21. An optional retention means 178 may be positioned distally from the implant 152 to prevent movement of the implant 152 during shipping or handling. Once the actuator 104 is beyond the protrusion 168, the implant 152 is primed for ejection by introduction to the lumen 154 of the needle 144, as shown in FIG. 22. The needle 144 may be modified, for example, with indent(s) 180 in the lumen 154 of the needle 144 to retain the implant 152 and prevent or eliminate accidental ejection or loss of the implant 152. In this configuration, the spring 122 provides for a tactile indication to the user that the implant 152 is primed for ejection as the actuator 104 is forced upwardly into the distal section 166 of the track 162 by the applied force of the spring 122. Further, the relative movement, or lack thereof of the implant 152 is observable in the transparent window 106 of housing 102, as shown in FIGS. 21 and 22. The transparent window 106 may contain a magnifying lens. In FIG. 22, the implant 152 is disposed in the lumen 154 of the needle 144 and is ready for ejection into a target site. Once the implant 152 is disposed thusly, a force generally aligned with the longitudinal axis 140 of the housing 102 applied to the actuator 104 causes movement of the actuator 104, which translates to movement of the plunger 120 and rod 132 from the distal section 166 of the track 162, thereby driving the implant 152 through the lumen 154 of needle 144 for ejection from the needle 144 and insertion into a target tissue, as shown in FIG. 20E.

Use of the embodiments of FIGS. 18 to 22 is substantially similar to that of the embodiment of FIGS. 1-11. To use the device 100, a user may insert the needle 144 of the device 100, when the device 100 is in the initial configuration, into a subject's eye. In the initial configuration, the user may verify that the implant 152 is disposed in the housing 102 by looking through the window 106 of the device 100. The user may then apply a downward and then a forward force to the actuator 104 to move the actuator 104 and hence the plunger 120 and rod 132 toward the distal end 156 of the housing 102. As described above, the plunger 120 is operatively connected to the rod 132, which, in turn, pushes the implant 152 through the lumen 154 of the needle 144 toward the target site. Thus, as the actuator 104 is moved toward the distal end 156 of the housing 102 by the user, the implant 152 is being driven through the lumen 154 of the needle 144 until it is ejected from the device 100.

From the initial configuration of FIG. 20A, the actuator 104 initially moves downwardly engaging the proximal section 164 of the track 162 when pressed by the user (FIG. 20B) and then moves toward the distal end 156 of the housing 102 under the protrusion 168 (FIG. 20C). Once the actuator 104 has moved beyond the protrusion 168, the implant 152 is primed for ejection. The user may verify that the implant 152 is no longer in the housing 102 by looking through the window 106 of the housing 102. After the user has moved the actuator 104 beyond the protrusion 168, the spring 122 forces the actuator 104 back up into the distal section 166 of the track 162 (FIG. 20D). The user may continue to press the actuator 104 toward the distal end 156 of the housing 102 to deliver the implant 152 to the target site (FIG. 20E). Preferably, the puncture site is self-sealing upon removal of the needle 144.

FIGS. 23 to 25 show the ocular implantation device in accordance with another alternative embodiment thereof wherein the actuator includes actuator tabs and the device does not include a spring. FIG. 23 is an exploded perspective view of the device and FIGS. 24A-D and 25 show the device in progressive stages of operation.

The device 200 comprises a housing 202, an actuator 204, a window 206, a plunger 208, a guide shaft assembly 210, and an optional cap 212. The housing 202 may comprise a right housing portion 214 and a left housing portion 216, which may be joined together to form the assembled housing 202. The plunger 208 is disposed within the housing 202 at a proximal end 218 thereof when the device 200 is assembled. The plunger 208 includes plunger openings 220, a closed end 222, and an open end 224 for receiving an extendedly projecting rod or wire 226. In addition, the open end 224 of the plunger 208 is dimensioned to be slidably received by a guide shaft 228.

The plunger 208 and the guide shaft assembly 210 are aligned with a longitudinal axis 230 of the housing 202. The guide shaft assembly 210 comprises the rod 206, the guide shaft 228, a needle stop 232, and a needle 234 and is disposed within the housing 202 when the housing 202 is assembled. The guide shaft 228 is fixedly positioned within and is supported by the housing 202, in particular by ribs 236 of the housing 202, when the device 200 is assembled. The rod 226 is dimensioned to fit concentrically within the guide shaft 228. The guide shaft 228 is preferably open at both ends 238, 240. One end 238 of the guide shaft 228 slidably receives the plunger 208 and the rod 226, and the other end 240 is fitted with the needle stop 232 for accommodating the rod 226 and an implant 242 prior to the implant 242 being moved into a lumen 244 (perhaps best shown in FIG. 25) of the needle 234. The needle stop 232 is axially aligned with the rod 226 and the guide shaft 228. The needle 234 is positioned within the needle stop 232 and projects from a distal end 246 of the housing 202. A retention means 248, shown in FIG. 25, may be disposed in the guide shaft 228 adjacent the implant 242 to prevent movement of the implant 242 during shipping or handling and to prevent inadvertent delivery of the implant 242. The optional cap 212 is frictionally attached to the housing 202 thereby shielding the needle 234 when the device 200 is not being used.

The actuator 204 is preferably positioned partially within the housing 202 and is translationally moveable along an elongated opening 250 in the housing 202. The actuator 204 may be operatively coupled to the plunger 208 via actuator tabs 252 positioned within the plunger openings 220. The actuator tabs 252 enable the actuator 204 to move in directions normal to the longitudinal axis of the housing 202 relative to the plunger 208 while the plunger 208 remains stationary in a plane of motion. The actuator 204 includes flanges 254 cooperatively engaging a track 256 disposed in the housing 202. The track 256 aids in guiding the actuator 204 during operation of the device 200. In the exemplary embodiment, the track 256 is divided into a continuous proximal upper section 258 and distal lower section 260. Because the proximal section 258 of the track 256 is relatively higher in the housing 202 than the distal section 260 of the track 256, an edge wall 266 demarcates the two sections 258, 260 along the track 256. Finger gripping means 262 are optionally disposed on an upper surface 264 of the actuator 204.

Referring to FIGS. 24A-D, in an initial configuration, (shown in FIG. 24A) the actuator 204 is initially positioned toward the proximal end 218 of the housing 202 with the actuator tabs 252 disposed within the plunger openings 220. During use, from the initial configuration, a user applies a force to the actuator 204 in a direction toward the distal end 246 of the housing 202 and generally aligned with the longitudinal axis 230 of the housing 202 causing the actuator 204 to move, which translates to movement of the plunger 208 with the rod 226 extending therefrom toward the distal end 246 of the housing 202. Movement is interrupted as the actuator flanges 254 reach the edge wall 266 of the track, as shown in FIG. 24B. Once the device 200 is in this configuration, the rod 226 is disposed adjacent the implant 242. From this configuration, a force in a generally normal direction relative to the longitudinal axis 230 of the housing 202 vertically translates the actuator flanges 254 downwardly for engagement with the distal lower track section 260 while the actuator tabs 252 extend through the plunger openings 220, as shown in FIG. 24C. Because the actuator tabs 252 are able to move relative to the plunger openings 220 in directions normal to the longitudinal axis 230 of the housing 202, the plunger 208 remains stationary while the actuator 204 moves downwardly relative to the longitudinal axis 230 of the housing 202. From this configuration, a force applied to the actuator 204 in a direction generally aligned with the longitudinal axis 230 of the housing 202 toward the distal end 246 of the housing 202 causes the rod 226 to urge the implant 242 from the retention means 248 and eject the implant 242 from the lumen 244 of needle 234, as shown in FIG. 24D. This action results in insertion of the implant 242 into the target tissue. As with the previously described embodiments, implant 242 translation or lack thereof may be observed using the transparent window 206.

To use the device 200, a user may insert the needle 234 of the device 200, when the device 200 is in the initial configuration, into a subject's eye. In the initial configuration, the user may verify that the implant 242 is disposed in the housing 202 by looking through the window 206 of the device 200. The user may then apply a forward force to the actuator 204 to move the actuator 204 and hence the plunger 208 and rod 226 toward the distal end 246 of the housing 202. As described above, the plunger 208 is operatively coupled to the rod 226, which, in turn, pushes the implant 242 through the lumen 244 of the needle 234 toward the target site. Thus, as the actuator 204 is moved toward the distal end 246 of the housing 246 by the user, the implant 242 is being driven through the lumen 244 of the needle 234 until it is ejected from the device 200.

From the initial configuration of FIG. 24A, the actuator 204 initially moves toward the distal end 246 of the housing 202 engaging the proximal upper section 258 of the track 256 when pressed by the user. Movement of the actuator 204 is interrupted when the actuator flanges 254 reach the edge wall 266 of the proximal upper track section 258, as shown in FIG. 24B. The user may press downwardly on the actuator 204 to move the actuator flanges 254 into engagement with the distal lower track section 260, as shown in FIG. 24C. The user may then push the actuator 204 toward the distal end 246 of the housing 202 to deliver the implant 242 to the target site (FIG. 24D). The user may verify that the implant 242 is no longer in the housing 202 by looking through the window 206 of the housing 202. Preferably, the puncture site is self-sealing upon removal of the needle 234.

FIGS. 26-27 depict the ocular implantation device in accordance with another alternative embodiment thereof wherein the needle is retractable. These figures show the device 300 in progressive stages of operation. The device 300 of FIGS. 26-27 is structurally similar to the device 10 of FIGS. 1 to 11, thus the same reference numerals will be used to designate components of the instant embodiment that are substantially similar to or the same as those of the embodiment of FIGS. 1 to 11. It will be understood by one of skill in the art that the retractable needle device 300 may have configurations that vary from the configuration shown in FIGS. 26-27. For example, the retractable needle device 300 may be made without a window, may have a simplified track system, or may be made without a rod.

In contrast to the embodiment of FIGS. 1 to 11, the needle 302 of the instant embodiment may be retracted into the distal end 76 of the housing 12. Thus, an implant 26 may be delivered with the instant device 300 by the needle 302 being retracted into the distal end 76 of the housing 12 rather than by the rod 46 pushing the implant 26 completely through the lumen of the needle 60 until it is delivered, as in previously described embodiments.

In FIG. 26, the device 300 is in an initial configuration, wherein the needle 302 is extended from the housing 12 with the implant 26 disposed in the lumen of the needle 302 ready for deployment into a target tissue. A user may apply a force to the actuator 20 that is generally aligned with the longitudinal axis 52 of the housing 12 but is in a direction moving away from the distal end 76 of the housing 12. Movement of the actuator 20 away from the distal end 76 of the housing 12 retracts the needle 60 into the housing 12 thereby deploying the implant 26 into the target tissue, as shown in FIG. 27. The needle 302 simply retracts back into the housing 12 leaving the implant 26 disposed in the target tissue. The retractable needle device 300 is advantageous because it offers control and predictability for the delivery location of an implant. A user may place the needle 302 at the location for desired delivery. When the needle 302 is retracted, the implant is left behind in the location that the needle 302 was in previously. In contrast, in an ocular implantation device embodiment wherein an implant is delivered by being forced out of a needle by a rod, the implant delivery location may be affected by the force with which the rod presses the implant or by the distance from the needle that the rod extends to eject the implant.

To use the device 300, a user may insert the needle 302 into a subject's eye. Then the user may press the actuator 20 away from the distal end 76 of the housing 12 to retract the needle 302 into the housing 12 thereby leaving the implant 26 in the target site (FIG. 27). Preferably, the puncture site is self-sealing upon removal of the needle 302.

The ocular implantation device disclosed herein may be provided as a kit with the implant preloaded into the implantation device. A kit may be provided that includes an implantation device preloaded with an implantable tube including a drug core contained therein with permeable coatings applied to each end of the tube. Alternatively, a kit may be provided that includes an implantation device preloaded with an implantable tube including a drug core contained therein with a permeable coating at one end of the tube and an impermeable member at the other end of the tube. The kit may also include saleable packaging for distribution and sale of the kit. It may further include auxiliary components, including, but not limited to, for example, components for properly disposing of the device, components for assisting in sterilizing an area around the injection site, and/or instructions for using the device.

The above-described ocular implantation device enables a healthcare provider to consistently deliver an implant to a subject. The device further enables the implant to be properly lodged or positioned in the target tissue. Advantageously, the device also ensures that the implant is positioned for delivery immediately prior to or commensurate with entry of the device into the target tissue because the implant is visually observable prior to activating or manipulating the device. The capability to push the actuator forward along the longitudinal axis of the device, with the needle in the subject's target tissue, and to observe that the implant is properly positioned for ejection into the target tissue results in better placement of the implant. Without the ability to visually observe that the implant is properly positioned prior to delivery, it can be difficult or, at the least, time consuming for a user to ensure that the implant has been delivered.

It will be understood to those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications, and publications cited herein are fully incorporated by reference herein in their entirety.

Claims

1. An ocular implantation device comprising:

(a) a housing having a longitudinal axis;
(b) a needle extending from said housing, wherein a lumen of said needle is configured to receive an implant;
(c) a plunger longitudinally disposed within said housing and a longitudinally extending rod operatively coupled thereto, wherein said plunger and said rod are collectively, translationally moveable along the longitudinal axis of said housing, and wherein said rod is configured to be receivable within at least a portion of the lumen;
(d) a continuous track disposed within the housing for aiding in controlling and facilitating delivery of the implant, the continuous track having a proximal section and a distal section divided by a protrusion;
(e) an actuator positioned partially within said housing, the actuator comprising flanges engaged with the continuous track;
(f) a spring operatively interconnected between said actuator and said plunger;
(g) a window disposed in said housing for visually determining a status of the implant; and
(h) a needle stop disposed at a distal end of the housing and axially aligned with the rod, said needle positioned within said needle stop;
(i) wherein said actuator is operatively engaged with said plunger and with said continuous track,
wherein movement of said actuator in a direction aligned with the longitudinal axis of said housing results in the translational movement of said plunger and said rod along the longitudinal axis of said housing,
wherein when said actuator is in a first position in the proximal section of the continuous track, said actuator is in abutting relation with said protrusion and said continuous track guides movement of said actuator in a direction normal to the longitudinal axis of said housing prior to the movement of said actuator in the direction aligned with the longitudinal axis of said housing resulting in the translational movement of said plunger and said rod along the longitudinal axis of said housing, and
wherein when said actuator is in a second position in the distal section of the continuous track, said continuous track guides the movement of said actuator in the direction aligned with the longitudinal axis of said housing for further translational movement of said plunger and said rod, and
wherein said protrusion and said continuous track are configured in such a way that the actuator can travel along the continuous track proximal and distal of said protrusion.

2. The ocular implantation device of claim 1, wherein said spring is a flat spring.

3. The ocular implantation device of claim 1, wherein said implant comprises a bioactive agent.

4. The ocular implantation device of claim 3, wherein the bioactive agent is fluocinolone acetonide.

5. The ocular implantation device of claim 1, further comprising retention means for preventing inadvertent delivery or displacement of the implant.

6. The ocular implantation device of claim 5, wherein the retention means is a core dam.

7. The ocular implantation device of claim 1, wherein said window comprises a magnifying lens.

8. A method of delivering an implant to an eye comprising:

(a) providing the device of claim 1 with said implant preloaded therein;
(b) inserting said needle of said device into said eye; and
(c) applying a force to said actuator of said device in order to deliver said implant to said eye.

9. The method of claim 8, further comprising using said window disposed in said housing of said device to determine the status of said implant.

10. A kit for delivering a tube shaped implant to an eye, comprising the device of claim 1 preloaded with the tube shaped implant including a drug core contained therein with permeable coatings applied to each end of a tube of the tube shaped implant.

11. A kit for delivering a tube shaped implant to an eye, comprising the device of claim 1 preloaded with the tube shaped implant including a drug core contained therein with a permeable coating at one end of a tube of the tube shaped implant and an impermeable member at another end of the tube of the tube shaped implant.

12. A method of delivering an implant to an eye comprising:

(a) providing said device of claim 1 with said implant preloaded therein;
(b) inserting said needle of said device into said eye; and
(c) applying a force to said actuator of said device in order to retract said needle of said device thereby delivering said implant to said eye.

13. The ocular implantation device of claim 1, wherein the needle is retractable.

14. An ocular implantation device comprising:

(a) a housing having a longitudinal axis;
(b) a needle extending longitudinally from said housing, said needle having a lumen extending therethrough, said lumen configured to receive an implant;
(c) a plunger longitudinally positioned within said housing and having a rod extending therefrom, wherein said plunger and said rod are translationally moveable along the longitudinal axis of said housing from an initial position, wherein said rod is receivable within at least a portion of said lumen;
(d) a guide shaft fixedly positioned within and supported by said housing in communication with said needle, said guide shaft cooperatively receiving said plunger and said rod upon the translational movement thereof;
(e) a guide tube positioned concentrically within at least a portion of the guide shaft, where said rod is dimensioned to fit concentrically within the guide tube;
(f) a needle stop disposed at a distal end of the housing and axially aligned with the rod, said needle positioned within said needle stop; and
(g) an actuator communicatively linked to said plunger, said actuator longitudinally moveable from a first position relative to said housing upon application to said actuator of a force aligned with the longitudinal axis of said housing,
wherein the movement of said actuator in a direction aligned with the longitudinal axis of said housing corresponds with the translational movement of said plunger from said initial position along the longitudinal axis of said housing; and
wherein said actuator is capable of movement in a direction normal to the longitudinal axis of said housing that does not result in the translational movement of said plunger and said rod.

15. The ocular implantation device of claim 14, further comprising a window disposed in said housing for visually determining a status of the implant.

Referenced Cited
U.S. Patent Documents
842631 January 1907 Deperdussin
3220413 November 1965 Sunnen
3238941 March 1966 Klein et al.
3698390 October 1972 Ferris
3921632 November 1975 Bardani
3937370 February 10, 1976 Witty
4077406 March 7, 1978 Sandhage et al.
4105030 August 8, 1978 Kercso
4144317 March 13, 1979 Higuchi et al.
4277888 July 14, 1981 Szabo
4447223 May 8, 1984 Kaye et al.
4451254 May 29, 1984 Dinius et al.
4597753 July 1, 1986 Turley
D287879 January 20, 1987 Braxton et al.
4659326 April 21, 1987 Johnson et al.
4668506 May 26, 1987 Bawa
4715373 December 29, 1987 Mazzocco et al.
4759359 July 26, 1988 Willis et al.
4799478 January 24, 1989 Fedorov et al.
4850970 July 25, 1989 Sutherland
4853224 August 1, 1989 Wong
4900304 February 13, 1990 Fujioka
4907587 March 13, 1990 Fedorov et al.
4915686 April 10, 1990 Frederick
4919130 April 24, 1990 Stoy et al.
4955889 September 11, 1990 Van Gent
4959217 September 25, 1990 Sanders et al.
4997652 March 5, 1991 Wong
5014717 May 14, 1991 Lohrmann
5059172 October 22, 1991 Sutherland et al.
5098439 March 24, 1992 Hill et al.
5098443 March 24, 1992 Parel et al.
5135493 August 4, 1992 Peschke
5164188 November 17, 1992 Wong
5178635 January 12, 1993 Gwon et al.
5190552 March 2, 1993 Kelman
5222972 June 29, 1993 Hill et al.
5250026 October 5, 1993 Ehrlich et al.
5279554 January 18, 1994 Turley
5284479 February 8, 1994 de Jong
5300114 April 5, 1994 Gwon et al.
5336206 August 9, 1994 Shichman
5378475 January 3, 1995 Smith
5451213 September 19, 1995 Teicher et al.
5466233 November 14, 1995 Weiner et al.
5476511 December 19, 1995 Gwon et al.
5494484 February 27, 1996 Feingold
5499987 March 19, 1996 Feingold
5562676 October 8, 1996 Brady et al.
5582613 December 10, 1996 Brady et al.
5584304 December 17, 1996 Brady
5616148 April 1, 1997 Eagles et al.
5620450 April 15, 1997 Eagles et al.
5643276 July 1, 1997 Zaleski
5653753 August 5, 1997 Brady et al.
5725521 March 10, 1998 Mueller
5735858 April 7, 1998 Makker et al.
5776138 July 7, 1998 Vidal et al.
5807400 September 15, 1998 Chambers et al.
5810833 September 22, 1998 Brady et al.
5824001 October 20, 1998 Erskine
5824072 October 20, 1998 Wong
D402031 December 1, 1998 Roberts et al.
D402757 December 15, 1998 Davis et al.
5876373 March 2, 1999 Giba et al.
5921989 July 13, 1999 Deacon et al.
5928245 July 27, 1999 Wolf et al.
5941250 August 24, 1999 Aramant et al.
5947975 September 7, 1999 Kikuchi et al.
5947976 September 7, 1999 Van Noy et al.
5957892 September 28, 1999 Thorne
6010510 January 4, 2000 Brown et al.
6051000 April 18, 2000 Heyman
6074397 June 13, 2000 Chambers et al.
6083231 July 4, 2000 Van Noy et al.
6093193 July 25, 2000 Makker et al.
6117443 September 12, 2000 Cherif-Cheikh
6120786 September 19, 2000 Cherif Cheikh
6129733 October 10, 2000 Brady et al.
6142972 November 7, 2000 Cheikh
6142995 November 7, 2000 Cosmescu
6143001 November 7, 2000 Brown et al.
D434558 December 5, 2000 Brady et al.
6159218 December 12, 2000 Aramant et al.
6179843 January 30, 2001 Weiler
6190350 February 20, 2001 Davis et al.
6203549 March 20, 2001 Waldock
6231603 May 15, 2001 Lang et al.
6238433 May 29, 2001 Portney
6251114 June 26, 2001 Farmer et al.
6267768 July 31, 2001 Deacon et al.
6280449 August 28, 2001 Blake
RE37387 September 18, 2001 Brady et al.
6355046 March 12, 2002 Kikuchi et al.
6375972 April 23, 2002 Guo et al.
6398789 June 4, 2002 Capetan
6413245 July 2, 2002 Yaacobi et al.
6428545 August 6, 2002 Portney
6439276 August 27, 2002 Wood et al.
D463555 September 24, 2002 Etter et al.
6447519 September 10, 2002 Brady et al.
6447520 September 10, 2002 Ott et al.
6503275 January 7, 2003 Cumming
6558395 May 6, 2003 Hjertman et al.
D475785 June 10, 2003 Chang
6579256 June 17, 2003 Hughes
6605093 August 12, 2003 Blake
6699285 March 2, 2004 Zapata
6723104 April 20, 2004 Ott
6770093 August 3, 2004 Worst et al.
6844343 January 18, 2005 Pfleiderer et al.
6858612 February 22, 2005 Pfleiderer et al.
D502542 March 1, 2005 Cohn et al.
6899717 May 31, 2005 Weber et al.
6923815 August 2, 2005 Brady et al.
6936053 August 30, 2005 Weiss
6960196 November 1, 2005 Prindle
7090681 August 15, 2006 Weber et al.
7097649 August 29, 2006 Meyer
7118552 October 10, 2006 Shaw et al.
7147644 December 12, 2006 Weber et al.
7217274 May 15, 2007 Meyer
7344554 March 18, 2008 Kuyava et al.
D568475 May 6, 2008 Sandel et al.
20010001822 May 24, 2001 Chambers et al.
20020026176 February 28, 2002 Varner et al.
20020151904 October 17, 2002 Feingold et al.
20020165610 November 7, 2002 Waldock
20020173756 November 21, 2002 Waldock
20030050647 March 13, 2003 Brady
20030054023 March 20, 2003 Hughes
20030078545 April 24, 2003 Howie et al.
20030171723 September 11, 2003 Ponzi
20030176870 September 18, 2003 Ott
20030204252 October 30, 2003 Paul et al.
20040054374 March 18, 2004 Weber et al.
20040097778 May 20, 2004 Hughett et al.
20040147938 July 29, 2004 Dusek et al.
20040215133 October 28, 2004 Weber et al.
20050033308 February 10, 2005 Callahan et al.
20050048099 March 3, 2005 Shiah
20050101967 May 12, 2005 Weber et al.
20050154399 July 14, 2005 Weber
20050203542 September 15, 2005 Weber et al.
20060004381 January 5, 2006 Feingold et al.
20060211982 September 21, 2006 Prestrelski et al.
20060235430 October 19, 2006 Le et al.
20060241650 October 26, 2006 Weber et al.
20070243230 October 18, 2007 De Juan, Jr. et al.
20070260201 November 8, 2007 Prausnitz et al.
20070260203 November 8, 2007 Donello et al.
20070287958 December 13, 2007 McKenzie et al.
20070293873 December 20, 2007 Chang
20080021412 January 24, 2008 Dos Santos et al.
20080021413 January 24, 2008 Dos Santos et al.
20080021419 January 24, 2008 Dacquay et al.
20080021438 January 24, 2008 Dacquay et al.
20080033351 February 7, 2008 Trogden et al.
20080071246 March 20, 2008 Nazzaro et al.
20080082121 April 3, 2008 Chu
20090105749 April 23, 2009 de Juan
20090131953 May 21, 2009 Quintin et al.
20100298807 November 25, 2010 Jansen et al.
Foreign Patent Documents
0 415 504 March 1991 EP
0 544 948 June 1993 EP
2001/0068277 March 2001 JP
2001/0516270 September 2001 JP
2002/0532209 October 2002 JP
2003/0230707 August 2003 JP
2005/0533619 November 2005 JP
2008/0528085 July 2008 JP
2008/0528088 July 2008 JP
WO 99/33512 July 1999 WO
WO 99/37247 July 1999 WO
WO 99/53991 October 1999 WO
WO 99/59668 November 1999 WO
WO 01/41685 June 2001 WO
WO 03/022174 March 2003 WO
WO 03/035136 May 2003 WO
WO 2004/073765 September 2004 WO
WO 2005/023154 March 2005 WO
WO 2006/077250 July 2006 WO
WO 2006/077349 July 2006 WO
WO 2007/024369 March 2007 WO
Other references
  • International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2008/082735; International Filing Date: Nov. 7, 2008; Date of Completion: Jan. 6, 2009; dated Jan. 16, 2009.
  • International Preliminary Report on Patentability of the International Searching Authority for International Application No. PCT/US2008/082735.
  • International Preliminary Report on Patentability, PCT/US2008/082735, filed Nov. 7, 2008, report dated May 11, 2010.
  • Supplementary European Search Report, EU App. No. 08846561, filed Nov. 7, 2008, search completed Nov. 26, 2012.
  • Communication for EU App. No. 08846561, filed Nov. 7, 2008, communication dated Jul. 24, 2013.
  • JP 2010533258, filed Nov. 7, 2008 Office Action dated Mar. 7, 2013.
  • CA 2705239, filed Nov. 7, 2008, Office Action dated Mar. 17, 2015.
  • Letter from China Patent Agent (H.K.) LTD. dated Mar. 23, 2012 and First Office Action for China Patent Application No. 200880124659.0, dated Feb. 15, 2012.
  • Letter from China Patent Agent (H.K.) LTD dated Dec. 27, 2012 and Second Office Action for China Patent Application No. 200880124659.0 dated Nov. 26, 2012.
  • Letter from Harrison Goddard Foote LLP dated Jan. 9, 2014 and Communication for EU Application No. 08 846 561.2-1662 dated Jan. 7, 2014.
  • Official Action for Canada Patent Application 2,705,239 dated Dec. 29, 2015.
  • Official Action for Canada Patent Application 2,705,239 dated Aug. 4, 2016.
Patent History
Patent number: 9849027
Type: Grant
Filed: Nov 7, 2008
Date of Patent: Dec 26, 2017
Patent Publication Number: 20090281520
Assignee: Alimera Sciences, Inc. (Alpharetta, GA)
Inventors: Brian Highley (Keller, TX), Morgan Beeson (Irving, TX), Randy Jackson (Irving, TX), Christopher Edward Wayman (Dallas, TX), Lance Shetler (Burleson, TX), Antonio Cutino (Cumming, GA), Michael Thomas Wright (Allen, TX)
Primary Examiner: Shefali Patel
Application Number: 12/266,699
Classifications
Current U.S. Class: Sliding Blade (30/162)
International Classification: A61F 9/00 (20060101); A61M 37/00 (20060101);